Nucleocapsid-specific antibodies as a correlate of protection against SARS-CoV-2 reinfection in children

Review Infectious Diseases

Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression

Niklas Bobrovitz et al.

Summary: This study aimed to evaluate the magnitude and duration of protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against infection and severe disease caused by the omicron variant. The results showed that previous infection provides short-term protection, while hybrid immunity has high and sustained protection against hospital admission or severe disease. These findings are important for determining the timing of vaccination and booster doses.

LANCET INFECTIOUS DISEASES (2023)

Add to Collection

Letter Medicine, General & Internal

Analysis of Previous Infection, Vaccinations, and Anti-SARS-CoV-2 Antibody Titers and Protection Against Infection With the SARS-CoV-2 Omicron BA.5 Variant

Shohei Yamamoto et al.

JAMA NETWORK OPEN (2023)

Add to Collection

Article Immunology

Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection

Alexander C. Dowell et al.

Summary: Children exhibit stronger and more sustained immune responses to SARS-CoV-2 infection, with higher levels of antibodies and T cell responses compared to adults, and the ability to neutralize various viral variants. These findings suggest that children may have a more robust immune system against the virus, potentially providing insight into the milder clinical presentation of SARS-CoV-2 in most children.

NATURE IMMUNOLOGY (2022)

Add to Collection

Article Pediatrics

Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England

Anna A. Mensah et al.

Summary: The risk of SARS-CoV-2 reinfection in children is lower than in adults, and reinfections are not associated with more severe disease or fatal outcomes.

LANCET CHILD & ADOLESCENT HEALTH (2022)

Add to Collection

Article Medicine, General & Internal

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age

Chandra J. Cohen-Stavi et al.

Summary: This study used data from Israel's largest healthcare organization and found that the BNT162b2 vaccine provides moderate protection against SARS-CoV-2 infection and symptomatic Covid-19 in children aged 5 to 11 during the omicron wave. The vaccine effectiveness ranged from 17% to 51% against documented infection and from 18% to 48% against symptomatic Covid-19. The youngest age group showed slightly better results.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Letter Medicine, General & Internal

Effects of Vaccination and Previous Infection on Omicron Infections in Children

Dan-Yu Lin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Cell Biology

Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models

Renee L. Hajnik et al.

Summary: This study reports a nucleoside-modified mRNA vaccine expressing the viral nucleoprotein, which shows modest control of SARS-CoV-2 when administered alone. However, combining this vaccine with a clinically proven mRNA vaccine expressing the spike protein induces robust protection against both Delta and Omicron variants.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

Recent infection with HCoV-OC43 may be associated with protection against SARS-CoV-2 infection

A. H. Ayesha Lavell et al.

Summary: A study in the Netherlands found that healthcare workers with high levels of HCoV-OC43 nucleocapsid antibodies had a lower risk of SARS-CoV-2 infection, which may support the development of pancoronavirus vaccines.

ISCIENCE (2022)

Add to Collection

Article Medicine, Research & Experimental

Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody

Tanushree Dangi et al.

Summary: This study demonstrates that nucleocapsid-specific antibodies can enhance control of SARS-CoV-2 infection and mediate antibody-dependent cellular cytotoxicity against infected cells. These findings provide a rationale for evaluating nucleocapsid-based monoclonal antibody therapies for the treatment of COVID-19.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Seasonal coronavirus protective immunity is short-lasting

Arthur W. D. Edridge et al.

NATURE MEDICINE (2020)

Add to Collection

Nucleocapsid-specific antibodies as a correlate of protection against SARS-CoV-2 reinfection in children

Related references

Export Citation

Share Paper